| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Lutikizumab Basic information |
| | Lutikizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lutikizumab Usage And Synthesis |
| Uses | Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis[1]. | | in vivo | Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1α and IL-1β[1]. | Animal Model: | Female C57/BL6 mice with IL-1α and IL-1β injection[1] | | Dosage: | 0.0001-1 mg/kg | | Administration: | Intraperitoneal injection, 0.0001-1 mg/kg, once | | Result: | Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1α and IL-1β. |
| | References | [1] Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7(3):605-19. DOI:10.1080/19420862.2015.1026501 |
| | Lutikizumab Preparation Products And Raw materials |
|